A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors

NCT03588650 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
26
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Shanghai Henlius Biotech